Clinical Trial Detail

NCT ID NCT03430063
Title A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Regeneron Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Ipilimumab + REGN2810

Cemiplimab

Age Groups: senior adult

Additional content available in CKB BOOST